News

Brain Tumour Support showcases early intervention work at BNOS 2026

2 July 2026 2 July 2026 | Campaigning and research

BNOS British Neuro-Oncology Society logo

Our Head of Support Services and CEO shared the importance of timely, personalised support for people affected by a brain tumour.

Brain Tumour Support was delighted to attend BNOS 2026 in Birmingham this week, joining healthcare professionals, researchers, charities and organisations from across the neuro-oncology community.

Taking place at the University of Birmingham from 1 to 3 July 2026, the British Neuro-Oncology Society annual meeting brings together leading voices from across the sector to share knowledge, explore new developments and discuss how care and outcomes can be improved for people affected by brain tumours.

On the first day of the conference, our Head of Support Services, Lucy Wilkinson, was joined by our CEO, Emma McKeown, to present Brain Tumour Support’s work on early support intervention for people affected by a brain tumour.

Their presentation highlighted the importance of providing timely, personalised support from the point of diagnosis, helping patients and families navigate the emotional, practical and everyday challenges they may face.

We were encouraged by the positive response to the presentation, with delegates recognising the value of integrating early support into the patient pathway. It was a valuable opportunity to share the impact of our work and contribute to important conversations about improving experiences for people living with a brain tumour.

Throughout the conference, we also had the opportunity to connect with fellow charities, healthcare professionals and other stakeholders. These conversations reinforced the importance of collaboration across the sector and opened up valuable opportunities to explore new partnerships and discuss ways we can continue to improve support for our community.

“BNOS is such an important opportunity to bring together everyone working to improve the lives of people affected by brain tumours. It was a privilege to present our work on early support intervention and to see such a positive response from colleagues across the neuro-oncology community.

“The conversations we have had have highlighted the real value of collaboration, and we are looking forward to building on the connections made at the conference.”

Lucy Wilkinson, Head of Support Services at Brain Tumour Support

We would like to thank the organisers of BNOS 2026 for hosting such an engaging and inspiring conference. We look forward to continuing our work to ensure that everyone affected by a brain tumour has access to the support they need, when they need it most.


Need support?

If you or someone you care about has been affected by a brain tumour, Brain Tumour Support is here to help. We provide personalised support, information and guidance from the point of diagnosis and beyond.

Get support

Related posts

29 July 2026 29 July 2026

Joint charity letter to Secretary of State for Health and Social Care

Brain tumour charities call for progress on research, treatment and support This month, we joined five other key organisations dedicated to helping the brain tumour community in writing a joint letter to the new Secretary of State for Health and…

Read

16 June 2026 16 June 2026

MPs speak with passion at Brain Cancer Justice petition debate

Brain Tumour Support has welcomed the powerful and emotive discussions that took place in Parliament yesterday (Monday 15 June), as the urgent need for greater investment in brain cancer research and treatment was debated. Securing this debate was a notable…

Read

21 May 2026 21 May 2026

Breaking down brain tumour terminology

When someone is diagnosed with a brain tumour, they may be overwhelmed by the need to understand a new language. This article aims to provide a shortcut to that new language so that patients, caregivers, colleagues, employers, journalists, policymakers and…

Read

31 March 2026 31 March 2026

Vorasidenib gains approval from NICE

At Brain Tumour Support, we have been closely following developments around Vorasidenib, a targeted therapy that has shown promise for people living with certain types of low-grade glioma. So we are delighted to share today’s final decision by the National…

Read